Wolverine Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Wolverine Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19	Closed	-$7.65K	–	1785
2024 Q4	$7.65K	Buy	+19	New	+$8.81K	﹤0.01%	1382
2021 Q3	–	Sell	-1,189	Closed	-$239K	–	2388
2021 Q2	$239K	Buy	1,189 +545	+85%	+$114K	﹤0.01%	1208
2021 Q1	$138K	Buy	644 +582	+939%	+$128K	﹤0.01%	1359
2020 Q4	$14K	Buy	+62	New	+$14.2K	﹤0.01%	1472
2020 Q3	–	Sell	-7	Closed	-$2K	–	1798
2020 Q2	$2K	Buy	+7	New	+$1.9K	﹤0.01%	1475
2017 Q4	–	Sell	-21,969	Closed	-$3.34M	–	1611
2017 Q3	$3.34M	Buy	21,969 +19,169	+685%	+$2.89M	0.04%	342
2017 Q2	$360K	Buy	+2,800	New	+$337K	﹤0.01%	855
2015 Q1	–	Sell	-889	Closed	-$105K	–	2224
2014 Q4	$105K	Sell	889 -64,000	-99%	-$7.21M	﹤0.01%	1175
2014 Q3	$7.29M	Hold	64,889	–	–	0.15%	127
2014 Q2	$6.14M	Buy	64,889 +500	+0.8%	+$35.1K	0.13%	126
2014 Q1	$4.55M	Buy	64,389 +39,900	+163%	+$3.16M	0.1%	166
2013 Q4	$1.82M	Buy	+24,489	New	+$1.71M	0.04%	356
2013 Q3	–	Sell	-2,965	Closed	-$236K	–	2893
2013 Q2	$237K	Buy	+2,965	New	+$218K	0.01%	1055

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wolverine Asset Management's VRTX Position: Q1 2025 in Review

Wolverine Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 19 shares — an estimated $7.65K sold.

Wolverine Asset Management first reported a position in VRTX in Q2 2013 and held it in 13 quarters. The position peaked at $7.29M in Q3 2014. 1,616 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Wolverine Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Wolverine Asset Management sold 19 Vertex Pharmaceuticals shares in Q1 2025, an estimated $7.65K.
Wolverine Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Wolverine Asset Management's Vertex Pharmaceuticals position peaked at $7.29M in Q3 2014.
1,616 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.